Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents

Therapeutic Delivery

Volumn 1, Issue 2, 2010, Pages 257-272

  Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINUCLEAR ANTIBODY; CAMPTOTHECIN DERIVATIVE; DOXORUBICIN; FENRETINIDE; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C5; NANOCARRIER; NUCLEOSOME AUTOANTIBODY; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE; PLATINUM COMPLEX; POLYMER; TETRAKIS(4 SULFOPHENYL)PORPHINE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIBODY SPECIFICITY; ASTROCYTOMA; BRAIN TUMOR; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CLINICAL EFFECTIVENESS; COLON ADENOCARCINOMA; COLON CANCER; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG COATING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; HUMAN; LEWIS CARCINOMA; LUNG METASTASIS; MELANOMA B16; MICELLE; MOLECULAR RECOGNITION; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

EID: 79955009083     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.30     Document Type: Review

References (150)

1. Friedman M, Stahl S. Engineered affinity proteins for tumour-targeting applications. Biotechnol. Appl. Biochem. 53(Pt 1), 1-29 (2009).
2. Stumpp MT, Amstutz P. DARPins: a true alternative to antibodies. Curr. Opin. Drug Discov. Devel. 10(2), 153-159 (2007). (Pubitemid 46438644)
3. Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin. Cancer Res. 11(9), 3567-3573 (2005). (Pubitemid 40627913)
4. Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 61(6), 2592-2601 (2001). (Pubitemid 32685844)
5. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2(4), 369-381 (2005). (Pubitemid 41277769)
6. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4(2), 145-160 (2005). (Pubitemid 40282557)
7. Torchilin VP. Drug targeting. Eur. J. Pharm. Sci. 11(Suppl. 2), S81-S91 (2000).
8. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin. Oncol. 31(6 Suppl. 13), 196-205 (2004). (Pubitemid 40023249)
9. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42(5), 439-462 (2003). (Pubitemid 36700404)
10. Kontermann RE. Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 8(1), 39-45 (2006). (Pubitemid 43230899)
11. Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin. Drug Deliv. 5(2), 189-204 (2008). (Pubitemid 351308311)
12. Torchilin VP, Khaw BA, Smirnov VN, Haber E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 89(4), 1114-1119 (1979).
13. Weissig V, Lasch J, Klibanov AL, Torchilin VP. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett. 202(1), 86-90 (1986). (Pubitemid 16051133)
14. Bogdanov AA Jr, Klibanov AL, Torchilin VP. Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N-hydroxysulfosuccinimide. FEBS Lett. 231(2), 381-384 (1988).
15. Holmberg E, Maruyama K, Litzinger DC et al. Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions. Biochem. Biophys. Res. Commun. 165(3), 1272-1278 (1989). (Pubitemid 20029846)
16. Lasch J, Niedermann G, Bogdanov AA, Torchilin VP. Thiolation of preformed liposomes with iminothiolane. FEBS Lett. 214(1), 13-16 (1987).
17. Niedermann G, Weissig V, Sternberg B, Lasch J. Carboxyacyl derivatives of cardiolipin as four-tailed hydrophobic anchors for the covalent coupling of hydrophilic proteins to liposomes. Biochim. Biophys. Acta 1070(2), 401-408 (1991).
18. Torchilin VP, Weissig V. Liposomes: A Practical Approach. Torchilin VP, Weissig V (Eds). Oxford University Press, Oxford, UK (2003).
19. Torchilin VP. Nanoparticulates as Pharmaceutical Carriers Torchilin VP (Ed.). Imperial College Press, London, UK (2006).
20. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237(2), 99-108 (1995).
21. Kamps JA, Scherphof GL. Receptor versus nonreceptor mediated clearance of liposomes. Adv. Drug Deliv. Rev. 32(1-2), 81-97 (1998). (Pubitemid 28277177)
22. Flavell DJ, Noss A, Pulford KA, Ling N, Flavell SU. Systemic therapy with 3bit, a triple combination cocktail of anti-CD19, -CD22 and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res. 57(21), 4824-4829 (1997). (Pubitemid 27468990)
23. Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled FAb' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413(1), 177-180 (1997). (Pubitemid 27348659)
24. Park JW, Hong K, Kirpotin DB et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8(4), 1172-1181 (2002). (Pubitemid 35177372)
25. Moreira JN, Gaspar R, Allen TM. Targeting stealth liposomes in a murine model of human small cell lung cancer. Biochim. Biophys. Acta 1515(2), 167-176 (2001). (Pubitemid 33086833)
26. Park JW, Kirpotin DB, Hong K et al. Tumor targeting using anti-HER2 immunoliposomes. J. Control. Release 74(1-3), 95-113 (2001). (Pubitemid 32727613)
27. Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732-6740 (2006). (Pubitemid 44085631)
28. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin. Cancer Res. 10(7), 2530-2537 (2004). (Pubitemid 38445715)
29. Kirpotin D, Park JW, Hong K et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry (Mosc.) 36(1), 66-75 (1997). (Pubitemid 27024679)
30. Yang T, Choi MK, Cui FD et al. Preparation and evaluation of paclitaxel-loaded pegylated immunoliposome. J. Control. Release 120(3), 169-177 (2007). (Pubitemid 47061489)
31. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58(15), 3320-3330 (1998). (Pubitemid 28371072)
32. Brignole C, Marimpietri D, Gambini C, Allen TM, Ponzoni M, Pastorino F. Development of FAb' fragments of anti-Gd2 immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. 197(1-2), 199-204 (2003). (Pubitemid 36860011)
33. Pastorino F, Brignole C, Marimpietri D et al. doxorubicin-loaded FAb fragments of antidisialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 63(1), 86-92 (2003). (Pubitemid 36070424)
34. Pastorino F, Brignole C, Di Paolo D et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 66(20), 10073-10082 (2006). (Pubitemid 44672061)
35. Raffaghello L, Pagnan G, Pastorino F et al. Immunoliposomal fenretinide: a novel anti-tumoral drug for human neuroblastoma. Cancer Lett. 197(1-2), 151-155 (2003). (Pubitemid 36860005)
36. Atobe K, Ishida T, Ishida E et al. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol. Pharm. Bull. 30(5), 972-978 (2007). (Pubitemid 46708651)
37. Mamot C, Drummond DC, Noble CO et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 65(24), 11631-11638 (2005). (Pubitemid 41821723)
38. Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Target. 14(4), 215-223 (2006).
39. Pan X, Lee RJ. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int. J. Pharm. 336(2), 276-283 (2007). (Pubitemid 46670654)
40. Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug. Chem. 18(1), 101-108 (2007). (Pubitemid 46145999)
41. Sugano M, Egilmez NK, Yokota SJ et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 60(24), 6942-6949 (2000). (Pubitemid 32059167)
42. Asgeirsdottir SA, Zwiers PJ, Morselt HW et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded abesel liposomes. Am. J. Physiol. Renal Physiol. 294(3), F554-F561 (2008). (Pubitemid 351442225)
43. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Anti-tumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer. Ther. 6(11), 3019-3027 (2007). (Pubitemid 350206780)
44. Marty C, Schwendener RA. Cytotoxic tumor targeting with scFv antibody-modified liposomes. Methods Mol. Med. 109, 389-402 (2005).
45. Volkel T, Holig P, Merdan T, Muller R, Kontermann RE. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim. Biophys. Acta 1663(1-2), 158-166 (2004). (Pubitemid 38625590)
46. Pan H, Han L, Chen W, Yao M, Lu W. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J. Control. Release 125(3), 228-235 (2008).
47. Matsumura Y, Hamaguchi T, Ura T et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91(10), 1775-1781 (2004). (Pubitemid 39664964)
48. Iakoubov L, Rokhlin O, Torchilin V. Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. Immunol. Lett. 47(1-2), 147-149 (1995).
49. Iakoubov L, Mongayt D, Torchilin VP. Monoclonal anti-nuclear autoantibody from the aged effectively suppresses tumor development in vivo. Cancer Biother. Radiopharm. 8, 299-310 (1995).
50. Iakoubov LZ, Torchilin VP. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res. 9(8), 439-446 (1997). (Pubitemid 127825997)
51. Cote RJ, Morrissey DM, Houghton AN, Beattie EJ Jr, Oettgen HF, Old LJ. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl Acad. Sci. USA. 80(7), 2026-2030 (1983). (Pubitemid 13079224)
52. Daar AS, Fabre JW. Organ-specific IgM autoantibodies to liver, heart and brain in man: generalized occurrence and possible functional significance in normal individuals and studies in patients with multiple sclerosis. Clin. Exp. Immunol. 45(1), 37-47 (1981). (Pubitemid 11072440)
53. Iakoubov LZ, Zakharova AV, Romanova NV, Cherepakhin VV, Rokhlin OV. Natural autoantibodies of neonatal rats detactable by the hybridoma technique. Biull. Eksp. Biol. Med. 106, 200-202 (1988).
54. Avrameas S. Natural autoantibodies: from horror autotoxicus' to gnothi seauton'. Immunol. Today 12(5), 154-159 (1991).
55. Sakharova AV, Iakubov LZ, Grivennikov IA, Romanova NV, Lobazina N. [Ontogenetic changes in the spectrum of specificities of natural monoclonal autoantibodies reacting with nerve tissue antigens]. Zh. Obshch. Biol. 47(5), 625-630 (1986).
56. Xavier RM, Yamauchi Y, Nakamura M et al. Antinuclear antibodies in healthy aging people: a prospective study. Mech. Ageing Dev. 78(2), 145-154 (1995).
57. Walford RL. Immunologic theory of aging: current status. Fed. Proc. 33(9), 2020-2027 (1974).
58. Globerson A, Tomer Y, Shoenfeld Y. Aging, natural autoantibodies, and autoimmunity. In:Natural Autoantibodies: Their Physiological Role and Regulatory Significance Shoenfeld Y, Isenberg DA (Eds). CRC Press Inc, London, UK, 59-79 (1993).
59. Pierotti MA, Colnaghi MI. Natural antibodies directed against murine lymphosarcoma cells: variability of level in individual mice. Int. J. Cancer 18(2), 223-229 (1976).
60. Martin SE, Martin WJ. Anti-tumour antibodies in normal mouse sera. Int. J. Cancer 15(4), 658-664 (1975).
61. Chow DA, Wolosin LB, Greenberg AH. Murine natural anti-tumor antibodies. II. The contribution of natural antibodies to tumor surveillance. Int. J. Cancer 27(4), 459-469 (1981). (Pubitemid 11159731)
62. Ben-Yehuda A, Weksler ME. Immune senescence: mechanisms and clinical implications. Cancer Invest. 10(6), 525-531 (1992).
63. Cammarata RJ, Rodnan GP, Fennell RH. Serum anti-g-globulin and antinuclear factors in the aged. JAMA 199(7), 455-458 (1967).
64. Hallgren HM, Buckley CE 3rd, Gilbertsen VA, Yunis EJ. Lymphocyte phytohemagglutinin responsiveness, immunoglobulins and autoantibodies in aging humans. J. Immunol. 111(4), 1101-1107 (1973).
65. Wiik A. Antinuclear factors in sera from healthy blood donors. Acta Pathol. Microbiol. Scand. C 84(3), 215-220 (1976).
66. Weksler ME, Tsuda T, Kim YT, Siskind GW. Immunobiology of aging and cancer. Cancer Detect. Prev. 14(6), 609-611 (1990).
67. Ziolkowska M, Nowak JJ, Ryzewska A. ADCC in aging rats with methylcholanthrene-induced sarcoma (MC-SA). Arch. Immunol. Ther. Exp. 35(6), 853-862 (1987).
68. Rekvig OP, Hannestad K. Certain polyclonal antinuclear antibodies cross-react with the surface membrane of human lymphocytes and granulocytes. Scand. J. Immunol. 6(10), 1041-1054 (1977). (Pubitemid 8198285)
69. Mecheri S, Dannecker G, Dennig D, Poncet P, Hoffmann MK. Anti-histone autoantibodies react specifically with the B cell surface. Mol. Immunol. 30(6), 549-557 (1993).
70. Raz E, Ben-Bassat H, Davidi T, Shlomai Z, Eilat D. Cross-reactions of anti-DNA autoantibodies with cell surface proteins. Eur. J. Immunol. 23(2), 383-390 (1993). (Pubitemid 23075067)
71. Iakoubov LZ, Torchilin VP. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect. Prev. 22(5), 470-475 (1998). (Pubitemid 28395565)
72. Pinto DM, Flaus A. Structure and function of histone H2AX. Subcell. Biochem. 50, 55-78 (2010).
73. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 116(2), 259-272 (2004). (Pubitemid 38167316)
74. Pereira SL, Reeve JN. Histones and nucleosomes in archaea and eukarya: a comparative analysis. Extremophiles 2(3), 141-148 (1998). (Pubitemid 28407992)
75. Jacob L, Viard JP. Anti-DNA antibodies and their relationships with antihistone and antinucleosome specificities. Eur. J. Med. 1(7), 425-431 (1992).
76. Koutouzov S, Cabrespines A, Amoura Z, Chabre H, Lotton C, Bach JF. Binding of nucleosomes to a cell surface receptor: redistribution and endocytosis in the presence of lupus antibodies. Eur. J. Immunol. 26(2), 472-486 (1996). (Pubitemid 26060258)
77. Seddiki N, Nato F, Lafaye P, Amoura Z, Piette JC, Mazie JC. Calreticulin, a potential cell surface receptor involved in cell penetration of anti-DNA antibodies. J. Immunol. 166(10), 6423-6429 (2001). (Pubitemid 32440777)
78. Emlen W, Holers VM, Arend WP, Kotzin B. Regulation of nuclear antigen expression on the cell surface of human monocytes. J. Immunol. 148(10), 3042-3048 (1992).
79. Bell DA, Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin. Immunol. Immunopathol. 60(1), 13-26 (1991).
80. Hefeneider SH, Cornell KA, Brown LE, Bakke AC, McCoy SL, Bennett RM. Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production. Clin. Immunol. Immunopathol. 63(3), 245-251 (1992).
81. Le Lann AD, Fournie GJ, Boissier L, Toutain PL, Benoist H. In vitro inhibition of natural-killer-mediated lysis by chromatin fragments. Cancer Immunol. Immunother. 39(3), 185-192 (1994). (Pubitemid 24298393)
82. Watson K, Gooderham NJ, Davies DS, Edwards RJ. Nucleosomes bind to cell surface proteoglycans. J. Biol. Chem. 274(31), 21707-21713 (1999).
83. Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5(6), 694-697 (1999). (Pubitemid 29289434)
84. Wyllie AH. Apoptosis (the 1992 Frank Rose memorial lecture). Br. J. Cancer 67(2), 205-208 (1993). (Pubitemid 23049537)
85. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 152(7), 3685-3692 (1994). (Pubitemid 24098067)
86. Licht R, van Bruggen MC, Oppers-Walgreen B, Rijke TP, Berden JH. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheum. 44(6), 1320-1330 (2001). (Pubitemid 32537530)
87. Trejo-Becerril C, Perez-Cardenas E, Trevino-Cuevas H et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int. J. Cancer 104(6), 663-668 (2003). (Pubitemid 36418501)
88. Bell R. What can we learn from herceptin trials in metastatic breast cancer? Oncology 63(Suppl. 1), 39-46 (2002).
89. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14(4), 520-535 (2003). (Pubitemid 41295078)
90. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol. Immunother. 52(5), 342-346 (2003). (Pubitemid 36578028)
91. Zelenetz AD. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin. Oncol. 30(2 Suppl. 4), 22-30 (2003). (Pubitemid 36505464)
92. Colnaghi MI, Menard S, Tagliabue E, Torre GD. Heterogeneity of the natural humoral anti-tumor immune response in mice as shown by monoclonal antibodies. J. Immunol. 128(6), 2757-2762 (1982). (Pubitemid 12124512)
93. David K, Ollert MW, Juhl H et al. Growth arrest of solid human neuroblastoma xenografts in nude rats by natural igm from healthy humans. Nat. Med. 2(6), 686-689 (1996). (Pubitemid 26191957)
94. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 63(22), 7995-8005 (2003). (Pubitemid 37466738)
95. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 22(8), 424-427 (2001). (Pubitemid 32709975)
96. Brinkman K, Termaat R, Berden JH, Smeenk RJ. Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol. Today 11(7), 232-234 (1990). (Pubitemid 20198986)
97. Johnson RJ, Shin HS. Monoclonal antibody against a differentiation antigen on human leukemia cells: cross-reactivity with rat leukemia and suppression of rat leukemia in vivo. J. Immunol. 130(6), 2930-2936 (1983). (Pubitemid 13107734)
98. Sorace JM, Johnson RJ. A cytotoxic monoclonal anti-leukemia antibody binds to histone H1. Hybridoma 9(5), 419-427 (1990). (Pubitemid 20378323)
99. Torchilin VP, Iakoubov LZ, Estrov Z. Therapeutic potential of antinuclear autoantibodies in cancer. J. Cancer Ther. 1, 179-190 (2003).
100. Lucisano YM, Mantovani B. Lysosomal enzyme release from polymorphonuclear leukocytes induced by immune complexes of IgM and of IgG. J. Immunol. 132(4), 2015-2020 (1984). (Pubitemid 14166676)
101. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416(6881), 603-607 (2002). (Pubitemid 34406754)
102. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. 168(5), 2240-2246 (2002). (Pubitemid 34171824)
103. Le Lann-Terrisse AD, Fournie GJ, Benoist H. Nucleosome-dependent escape of tumor cells from natural-killer-mediated lysis: nucleosomes are taken up by target cells and act at a postconjugation level. Cancer Immunol. Immunother. 43(6), 337-344 (1997). (Pubitemid 27102219)
104. Blaes F, Klotz M, Huwer H et al. Antineural and antinuclear autoantibodies are of prognostic relevance in nonsmall cell lung cancer. Ann. Thorac. Surg. 69(1), 254-258 (2000). (Pubitemid 30078859)
105. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, Varsamidakis N, Machairas A, Mandrekas D. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 20(6B), 4351-4353 (2000). (Pubitemid 32141785)
106. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon-a therapy in chronic myelogenous leukemia. J. Clin. Oncol. 13(9), 2401-2407 (1995).
107. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl Acad. Sci. USA 100(10), 6039-6044 (2003). (Pubitemid 36576927)
108. Gupta B, Levchenko TS, Mongayt DA, Torchilin VP. Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo. J. Drug Target. 13(6), 337-343 (2005). (Pubitemid 41683987)
109. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP: Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control. Release 100(1), 135-144 (2004). (Pubitemid 39445991)
110. Chakilam AR, Pabba S, Mongayt D, Iakoubov LZ, Torchilin VP. A single monoclonal antinuclear autoantibody with nucleosome-restricted specificity inhibits growth of diverse human tumors in nude mice. Cancer Ther. 2, 353-364 (2004).
111. Elbayoumi TA, Torchilin VP. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: g-imaging studies. Eur. J. Nucl. Med. Mol. Imaging 33(10), 1196-1205 (2006). (Pubitemid 44484476)
112. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62(24), 7190-7194 (2002). (Pubitemid 36025236)
113. Xiong XB, Huang Y, Lu WL et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved anti-tumor efficacy: in vitro and in vivo. J. Pharm. Sci. 94(8), 1782-1793 (2005). (Pubitemid 41360872)
114. Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm. Res. 22(6), 933-939 (2005). (Pubitemid 40898103)
115. Huang SK, Stauffer PR, Hong K et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 54(8), 2186-2191 (1994). (Pubitemid 24138693)
116. Papahadjopoulos D, Allen TM, Gabizon A et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl Acad. Sci. USA 88(24), 11460-11464 (1991). (Pubitemid 21916061)
117. Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded pegylated liposomes against various tumor cell lines. Eur. J. Pharm. Sci. 32(3), 159-168 (2007). (Pubitemid 47532709)
118. Elbayoumi TA, Torchilin VP. Tumor-specific antinucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol. Pharm. 6(1), 246-254 (2009).
119. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res. 15(6), 1973-1980 (2009).
120. Chabner BA. Cancer Chemotherapy: Principles and Practice. Chabner BA, Collings JM (Eds). Lippincott, Williams & Wilkins Philadelphia, PA, USA (1990).
121. Yokogawa K, Nakashima E, Ishizaki J, Maeda H, Nagano T, Ichimura F. Relationships in the structure-tissue distribution of basic drugs in the rabbit. Pharm. Res. 7(7), 691-696 (1990). (Pubitemid 20278364)
122. Hageluken A, Grunbaum L, Nurnberg B, Harhammer R, Schunack W, Seifert R. Lipophilic b-adrenoceptor antagonists and local anesthetics are effective direct activators of G-proteins. Biochem. Pharmacol. 47(10), 1789-1795 (1994).
123. Fernandez AM, Van Derpoorten K, Dasnois L et al. N-succinyl-(b-alanyl-l- leucyl-l-alanyl-l-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J. Med. Chem. 44(22), 3750-3753 (2001). (Pubitemid 33026683)
124. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24(1), 1-16 (2007). (Pubitemid 44902565)
125. Muranishi S. Absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 7(1), 1-33 (1990). (Pubitemid 20355576)
126. Hammad MA, Muller BW. Solubility and stability of tetrazepam in mixed micelles. Eur. J. Pharm. Sci. 7(1), 49-55 (1998). (Pubitemid 29056226)
127. Palmer TN, Caride VJ, Caldecourt MA, Twickler J, Abdullah V. The mechanism of liposome accumulation in infarction. Biochim. Biophys. Acta 797(3), 363-368 (1984). (Pubitemid 14194902)
128. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv. Drug Deliv. Rev. 16, 285-294 (1995).
129. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54(13), 3352-3356 (1994). (Pubitemid 24225946)
130. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1-2), 271-284 (2000). (Pubitemid 30122932)
131. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74(1-3), 47-61 (2001). (Pubitemid 32727608)
132. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48(2), 101-111 (1999). (Pubitemid 29401986)
133. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 73(2-3), 137-172 (2001). (Pubitemid 32544594)
134. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3(2), 123-193 (1987). (Pubitemid 17219201)
135. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating? Adv. Drug Deliv. Rev. 16(2), 141-155 (1995).
136. Trubetskoy VS, Torchilin VP. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv. Drug Deliv. Rev. 16, 311-320 (1995).
137. Torchilin VP, Levchenko TS, Lukyanov AN et al. P-nitrophenylcarbonyl-PEG- PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via P-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511(2), 397-411 (2001). (Pubitemid 32250227)
138. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. Tat peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl Acad. Sci. USA 98(15), 8786-8791 (2001). (Pubitemid 32678105)
139. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J. Drug Target. 11(2), 87-92 (2003). (Pubitemid 36869181)
140. Sawant RR, Sawant RM, Torchilin VP. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur. J. Pharm. Biopharm. 70(1), 51-57 (2008).
141. Skidan I, Miao B, Thekkedath RV, Dholakia P, Degterev A, Torchilin V. In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with trail. Drug Deliv. 16(1), 45-51 (2009).
142. Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur. J. Pharm. Biopharm. 62(3), 235-240 (2006). (Pubitemid 43356570)
143. Roby A, Erdogan S, Torchilin VP. Enhanced in vivo anti-tumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biol. Ther. 6(7), (2007).
144. Skidan I, Dholakia P, Torchilin V. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. J. Drug Target. 16(6), 486-493 (2008). (Pubitemid 352015817)
145. Ljubimova JY, Fujita M, Ljubimov AV, Torchilin VP, Black KL, Holler E. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine 3(2), 247-265 (2008). (Pubitemid 351611858)
146. Sawant RM, Sawant RR, Gultepe E et al. Nanosized cancer cell-targeted polymeric immunomicelles loaded with supermagnetic iron oxide nanoparticles. J. Nanopart. Res. 11(7), 1777-1785 (2009).
147. Erdogan S, Roby A, Torchilin VP. Enhanced tumor visualization by g-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. Mol. Pharm. 3(5), 525-530 (2006). (Pubitemid 44639129)
148. Erdogan S, Roby A, Sawant R, Hurley J, Torchilin VP. Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J. Liposome Res. 16(1), 45-55 (2006).
149. Erdogan S, Medarova ZO, Roby A, Moore A, Torchilin VP. Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J. Magn. Reson. Imaging 27(3), 574-580 (2008). (Pubitemid 351354743)
150. Sawant RM, Hurley JP, Salmaso S et al. Smart' drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17(4), 943-949 (2006). (Pubitemid 44162612)